Search

A study conducted in Alexandria, Egypt, has provided new insights into the Chikungunya virus (CHIKV), which is known for causing severe joint pain, fever, headache, muscle pain, and rash. The study focused on developing a biomedical sensor using photonic crystal fiber technology that can accurately detect the CHIKV virus in blood samples. The sensor demonstrated high sensitivity and minimal losses compared to other biosensors. The research concluded with a comparison analysis to validate the reliability and effectiveness of the sensor. This study was supported by the Alexandria Higher Institute of Engineering Studies and has been peer-reviewed. [Extracted from the article]

This article discusses the findings of a study on the tropism of arboviruses, specifically the chikungunya virus (CHIKV) and the Mayaro virus (MAYV), in human primary cardiac cells. The study found that while MAYV was able to replicate in various types of human cardiac cells, CHIKV was completely restricted in all endothelial cells tested. The researchers also observed that MAYV may be more efficient in evading the innate immune response in human cardiac endothelial cells. Further research is needed to understand the impact of these findings on pathogenesis and the specific host factors involved. [Extracted from the article]

A new study conducted by researchers at Addis Ababa University in Ethiopia has found a high prevalence of chikungunya virus infection among patients with acute febrile illness in the Afar Region. Chikungunya is a disease caused by the chikungunya virus, which is transmitted by Aedes mosquitoes. The study collected data from 368 febrile patients and found that 47.8% had acute chikungunya virus infection, while 6.3% had previous exposure. The researchers recommend regular screening for arbovirus infection in febrile patients to control and mitigate the spread of chikungunya. [Extracted from the article]

A researcher from the Pasteur Institute in Paris has published new studies and findings on the Chikungunya virus, an RNA virus transmitted by mosquitoes that poses a threat to humans. The researcher investigated the impact of viral RNA secondary structures on the production of defective viral genomes (DVGs), which are non-functional genomes that can inhibit viral replication. Through experimental mapping of RNA secondary structures, the researcher found that unpaired nucleotides within the secondary structure increased the probability of DVG generation. The study also showed that disrupting the RNA secondary structure altered DVG generation. This research provides insights into the replication of the Chikungunya virus and its potential implications for therapy. [Extracted from the article]

This article discusses a study on alphaviruses, which are RNA viruses that require transmission between arthropod and vertebrate hosts for their propagation. The study focuses on the conservation of an opal termination codon in the nonstructural protein 3 (nsP3) of alphaviruses. The researchers found that the opal codon is preferred over other codons in primate cells at higher temperatures, but this preference is diminished in mosquito and primate cells at lower temperatures. The opal codon allows for optimal protein production and processing, but substituting it with other codons disrupts these processes. The study highlights the intricate strategy that alphaviruses use to optimize their fitness. [Extracted from the article]

A recent report from Naval Medical University in Shanghai, China, highlights the potential of nifuroxazide, an FDA-approved antibiotic, as a treatment for Chikungunya virus (CHIKV) infection. CHIKV is a reemerging arbovirus that causes disease on a global scale, with no approved antiviral therapies currently available. The study found that nifuroxazide significantly inhibited the replication of various arboviruses, including CHIKV, yellow fever virus (YFV), tick-borne encephalitis virus (TBEV), and west nile virus (WNV). In vivo experiments showed that nifuroxazide reduced viral load and protected mice from CHIKV-induced footpad swelling. These findings suggest that nifuroxazide has potential as an antiviral drug for the treatment of CHIKV infection. [Extracted from the article]

A report from the University of Sao Paulo discusses the immunopathology and immune evasion strategies of alphaviruses, with a focus on their potential neurological implications. The researchers explore how these viruses manipulate the host immune response, modulate inflammatory pathways, and establish persistent infections. They also investigate the ability of alphaviruses to breach the blood-brain barrier and the impact of co-infections on neurological outcomes. The study emphasizes the need for further research to understand the complexities of virus-host interactions and develop targeted therapies for joint and neurological manifestations of alphavirus infections. [Extracted from the article]

A recent study conducted by researchers at Kunming University of Science and Technology in China has developed a new method for the rapid and sensitive detection of the Chikungunya virus (CHIKV). The study combines a one-tube, reverse transcription semi-nested multi-enzyme isothermal rapid amplification assay with lateral flow dipstick strips to detect CHIKV RNA. This method has a sensitivity of 1 copy/mL, which is 100-fold higher than conventional methods. The technique is faster, does not require special equipment, and offers the potential for rapid, on-site, low-cost molecular diagnosis of CHIKV. [Extracted from the article]

Researchers from Government College University Faisalabad have conducted a study on the Chikungunya virus (CHIKV) using bioinformatics. CHIKV is an RNA virus that causes Chikungunya fever. The researchers used an in-silico approach to predict that CHIKV produces micro-RNAs that target host-specific genes associated with host cellular regulatory pathways. They identified hub genes and found that certain genes were down-regulated while others were up-regulated. These findings provide insight into potential targets for therapeutic intervention and the development of effective treatments for CHIKV-mediated diseases. [Extracted from the article]

A recent report from Prince Sattam Bin Abdulaziz University in Saudi Arabia discusses the neurological manifestations of vector-borne viruses, such as the Chikungunya virus. These viruses are transmitted to humans through the bites of infected arthropods like mosquitoes and ticks. The report highlights the range of clinical symptoms associated with these viruses, from mild to severe, and discusses the mechanisms by which they invade the central nervous system and trigger neuroinflammatory responses. The researchers emphasize the importance of early detection and advanced laboratory testing for diagnosing these neurological complications. [Extracted from the article]

Researchers at Harvard Medical School have published a new report on the eastern equine encephalitis virus (EEEV), which is the most virulent alphavirus that infects humans. Many survivors of EEEV develop neurological sequelae, including paralysis and intellectual disability. The researchers used cryo-electron microscopy to determine the structures of the EEEV spike glycoproteins bound to the ligand-binding domain of the very-low density lipoprotein receptor (VLDLR), which is a cellular receptor for EEEV. The study suggests that the ability of LDLR-related proteins to interact with viral spike proteins through small footprints with flexible binding modes allows for the acquisition of LDLR-related proteins as cellular receptors for diverse sets of viruses. [Extracted from the article]

A recent preprint study investigated the role of chemokine C ligand 4 (CCL4) and its receptor C-C chemokine receptor type 5 (CCR5) in arthritogenic alphavirus disease. The study focused on alphaviruses such as chikungunya virus (CHIKV), Mayaro virus (MAYV), Ross River virus (RRV), and O nyong nyong virus (ONNV), which cause fever, rash, and joint swelling. The researchers found that CCL4 and CCR5 did not have a significant impact on disease progression or virus replication in mice infected with MAYV. These findings suggest that CCL4 and CCR5 may not play a major role in the development of arthritogenic alphavirus disease. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

A recent study conducted by the Institute for Disease Modeling found that the introduction of the rubella-containing vaccine (RCV) does not increase the risk of congenital rubella syndrome (CRS). Rubella infection during pregnancy can lead to miscarriage, stillbirth, or CRS. The study used simulations to determine the expected future trajectories of disease burden and found that introducing RCV reduces both rubella virus transmission and disease burden for around 15 years. The risk of increased disease burden only exists in contexts with persistently high transmission intensity. Overall, the study supports the introduction of RCV as it significantly reduces the burden of rubella. [Extracted from the article]

A recent study conducted by the Paul-Ehrlich-Institute in Germany has provided new insights into the replication of the Ross River virus (RRV). The researchers constructed a recombinant RRV that allowed for real-time imaging of viral replication. They found that the presence or absence of a stop codon after the nsP3 gene did not affect the replication capacity of the virus. However, there was a cell type-dependent delay in RRV replication in HEK 293T cells, which was caused by an inhibitor called ZAP. The study suggests that viral replication of alphaviruses is unique to each virus and dependent on the cell type. [Extracted from the article]

A recent study conducted by researchers at Universidad Cooperativa de Colombia has investigated the antiviral properties of L-tyrosine derivatives against the Chikungunya virus (CHIKV). The study found that six dihalogenated compounds derived from L-tyrosine were effective in inhibiting CHIKV infection in vitro. These compounds were shown to decrease the expression of viral proteins, inhibit the viral genome, and reduce the adhesion and internalization of the virus. One compound, C3, was particularly promising as it inhibited CHIKV infection at different stages of the replicative cycle. This research provides valuable insights into potential treatments for CHIKV, a disease for which there are currently no authorized antivirals. [Extracted from the article]

A recent research article from Y.B. Chavan College of Pharmacy in Maharashtra, India, discusses the Chikungunya virus (CHIKV) and the need for an effective vaccine. The article explores various vaccine candidates, including live attenuated, killed, nucleic acid-based, virus-like particle, chimeric, subunit, and adenovirus vectored vaccines. RNA vaccines are highlighted as promising candidates due to their rapid response capabilities and enhanced safety profile. The study also examines potential antiviral targets and the roles of Toll-like receptors, RIG-I, and NOD-like receptors in the immune response to CHIKV. The article concludes by discussing the significance of E1 and E2 proteins, monoclonal antibodies, and RNA vaccines as prospective CHIKV vaccine candidates. [Extracted from the article]

A new report from the University of Georgia presents fresh data on the Ebola virus. The study focuses on the role of T-cell immunoglobin and mucin domain protein-1 (TIM-1) in the entry and release of chikungunya virus (CHIKV). The researchers found that TIM-1 receptors on the surface of host cells significantly reduced CHIKV release efficiency. However, CHIKV was able to counteract this effect over the course of infection. The findings could aid in the development of cell lines for enhanced vaccine production. [Extracted from the article]

A recent study conducted by researchers at the Shenzhen Institute for Drug Control in China explores the potential of a recombinant GM-CSF-carrying Sindbis virus, called SINV-GM-CSF, for the treatment of hepatocellular carcinoma (liver cancer). The study found that the Sindbis virus effectively infected liver cancer cell lines and induced cell death. Additionally, the addition of GM-CSF enhanced the tumor-killing effect of the virus and increased the number of immune cells in the tumor microenvironment. The researchers concluded that SINV-GM-CSF shows promise as a safe and effective oncolytic virus for liver cancer therapy. [Extracted from the article]

A recent study published in the journal Emerging Infectious Diseases has found that the Mayaro and chikungunya viruses are co-circulating in Roraima, Brazil's northernmost state and part of the Amazon biome. This discovery challenges the belief that infection by one virus would provide protection against the other. The researchers emphasize the need for enhanced surveillance and diagnostic methods to detect and monitor these arboviruses, as their symptoms are similar and can be hard to distinguish clinically. The study was part of a larger project called Amazon+10, which aims to understand the dynamics of viral circulation in forest areas and promote sustainable development in the Amazon region. [Extracted from the article]

The patent application titled "Alphavirus Vectors Containing Universal Cloning Adaptors" discusses the development of immuno-therapeutics for the prevention and management of health conditions like cancer and microbial infection. The application focuses on nucleic acid constructs that contain a modified alphavirus genome or replicon RNA, with a synthetic adaptor molecule replacing a portion of the viral structural protein sequence. These constructs allow for the insertion of a different sequence and have potential applications in gene therapy, vaccine delivery, and drug delivery. The application provides detailed information about the constructs and their potential uses in gene therapy and viral research. [Extracted from the article]

A recent study published on biorxiv.org explores the role of Musashi RNA binding protein-2 (MSI-2) in the replication of the Chikungunya virus (CHIKV). The researchers found that MSI-2 is a proviral factor that is essential for efficient CHIKV genome replication. They also discovered that MSI-2 interacts specifically with an RNA binding motif within the 5' untranslated region (5' UTR) of CHIKV. This study provides new insights into the mechanisms controlling the replication of CHIKV and suggests MSI RNA binding proteins as a potential therapeutic target. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

This document is a patent application for a method and composition that aims to enhance gene expression in animal and other eukaryotic cells. The method involves introducing a nucleic acid molecule into the cell, which includes a viral capsid enhancer and a coding sequence for a gene of interest. The viral capsid enhancer is derived from either an alphavirus or a virus species belonging to the Arterivirus genus. The invention has the potential to improve genetic modifications in cells and organisms, allowing for the development of genetically enhanced cells and organisms with desirable traits. The patent application provides various embodiments and examples of these molecules, including those derived from alphaviruses and arteriviruses, with the goal of improving gene expression for therapeutic, diagnostic, and industrial applications. [Extracted from the article]

A recent study conducted by the National Institute for Virology in Pune, India, has found that zinc and magnesium salts have potential antiviral effects against the Chikungunya virus (CHIKV). The study revealed that zinc salts exert their antiviral activity at the entry and post-entry stages of the virus's life cycle, while magnesium salts affect the virus at post-entry stages. These findings suggest that zinc and magnesium salts could be used in the development of therapeutic strategies for early treatment of chikungunya patients, potentially reducing the risk of persistent arthritis associated with the virus. [Extracted from the article]

A report from the ICMR-National Institute of Virology in Pune, India, discusses the efforts to eliminate rubella and congenital rubella syndrome (CRS) in India by 2023. The researchers conducted serosurveys among pregnant women to monitor rubella immunity and estimate the burden of CRS in India after a nationwide measles and rubella vaccination campaign. The study found that rubella seroprevalence among pregnant women in 2022 was 85.2%, and the estimated annual incidence of CRS declined significantly following the vaccination campaign. However, about 15% of women of childbearing age in India still lack immunity to rubella, highlighting the need for continued high rates of rubella vaccination among children to prevent rubella virus exposure in susceptible women. [Extracted from the article]

Valneva SE has been issued a patent for a method of producing pharmaceutical compositions comprising immunogenic chikungunya virus CHIKV-delta5NSP3. Chikungunya virus is a mosquito-borne virus that causes fever, rash, fatigue, and severe joint pain. Currently, there are no vaccines or medications available for the prevention or treatment of chikungunya virus disease. The patent describes a pharmaceutical composition that includes live attenuated CHIKV-D5nsP3 particles, which have been altered to reduce virulence but still maintain immunogenicity. The composition aims to elicit a neutralizing immune response in a subject, providing protection against infection and disease caused by chikungunya virus. [Extracted from the article]

A study conducted by the Oswaldo Cruz Institute (FIOCRUZ) in Brazil investigated the transmission of the Oropouche virus (OROV) during the introduction of the Chikungunya virus (CHIKV) in the state of Amapa in the Brazilian Amazon. The researchers found that while no acute cases of OROV were detected, 10.24% of the febrile patients tested positive for neutralizing antibodies for OROV, indicating previous exposure. Additionally, 20.25% of the patients tested positive for CHIKV RNA, suggesting recent exposure. The study highlights the challenge of diagnosing arbovirus infections due to their similar clinical signs and symptoms, and emphasizes the importance of surveillance for these diseases in Brazil. [Extracted from the article]